Do you have Cutaneous T-cell Lymphoma (CTCL)?
The Department of Dermatology at UConn Health is conducting a research study testing two concentrations of an investigational gel, resiquimod, compared to placebo (inactive substance), for the treatment of cutaneous T-cell lymphoma. In order to qualify, participants must have a clinical diagnosis of stage IA, IB, or IIA CTCL with at least three distinct patches, including one ‘distant’ patch that is at least 10 centimeters away from other patches. There is no cost to participate in this research study, and eligible participants will receive a travel allowance of $55.00 or $110.00 per completed trial visit.
If you or someone you know is at least 18 years of age and has been diagnosed with stage IA, IB, or IIA cutaneous T-cell lymphoma, please contact:
Cheryl Martin, RN, Research Coordinator for Dr. Bruce Strober, at 860-679-3475
IRB # W18-078-1 “A randomized, double-blind, multi-centre, placebo-controlled, parallel-arm phase 2 trial to assess safety, efficacy and pharmacokinetics of CD11301 0.03% and 0.06% gel in the treatment of Cutaneous T-Cell Lymphoma (CTCL), stages IA, IB and IIA”
For more information, contact: Cheryl Martin RN, Research Coordinator for Dr. Bruce Strober at 860 679-3475 cmartin@uchc.edu